Adoption of the 2024 Dutch statutory annual accounts for the fiscal year ended December 31, 2024.
Discharge of liability of the members of the Board for their management during the fiscal year ended December 31, 2024.
Reappointment of Robert Gut, M.D., Ph.D. as non-executive director.
Reappointment of Matthew Kapusta as executive director.
Reappointment of Jeremy Springhorn, Ph.D. as non-executive director.
Authorization of the Board as the competent body to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares.
Authorization of the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares.
Authorization of the Board to repurchase Ordinary Shares.
Appointment of KPMG as external auditor of the Company for the financial year 2025.
Approval, on an advisory basis, of the compensation of the named executive officers of the Company.
Resolution to adopt the Amendment and Restatement of the 2014 Share Incentive Plan.